Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986263 in Adults With Advanced Hepatic Fibrosis After Virologic Cure of Hepatitis C
NCT03420768 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986263 in Adults With Advanced Hepatic Fibrosis After Virologic Cure of Hepatitis C
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 14, 2018
- Completion date
- May 28, 2019
- Enrollment
- 61 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatic cirrhosis, liver fibrosis